Vita Life Sciences Limited
ASX: VLS
Strong growth outlook but weakening momentum signals limited near-term upside potential.
(Source: TradingView) 3-Month Performance Profile of VLS on a DTF compared to S&P/ASX 200 (XJO).
Vita Life Sciences reported strong FY2025 results, with revenue increasing about 17% year-on-year to $93.3 million and EBITDA rising around 19% to $14.8 mi
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
